Morgantown, West Virginia, October 7, 2009 — Protea Biosciences, Inc., today announced that Steve Turner, its President and Chief Executive Officer, will present at the 2009 Boston Biotech R&D Conference, at 3:40pm on Tuesday, October 27, 2009 at the Harvard Medical School in Boston, Mass. His presentation is titled “Protea – building a new proteomics franchise.” The conference will bring faculty from top academic institutions together with executives from several of the Boston area’s emerging biopharmaceutical companies, as well as members of the Biotechnology investment banking community.
“We are pleased to be selected as a participant in the 2009 Annual Boston Biotechnology R&D Conference,” said Steve Turner. “This prestigious conference is an excellent forum to meet with other leading biotech and pharmaceutical companies and to highlight the progress our company has made in the field of proteomics.”
“Working in our Morgantown, West Virginia laboratories, our scientists have made important advances in the field of proteomics, which we apply to the development of new biopharmaceuticals and life science products,” Mr. Turner said. “All biological functions are carried out by proteins, and disease-associated protein targets are the therapeutic points of intervention, or targets, for the drug development process. Our field is critical to the future of pharmaceutical development,” he added.
The Conference program includes several luminaries in medical research, as well as executives representing the next generation of leading biotech and pharma companies. Jonathan Kraft, President and Chief Executive Officer of The Kraft Group and President of the New England Patriots, will provide the keynote address. The conference is being organized by Christoph Westphal, M.D., Ph.D., Chief Executive Officer of Sirtris, a GlaxoSmithKline (GSK) company, and Senior Vice President of the Center of Excellence for External Drug Discovery (CEEDD), GSK, and Michelle Dipp, M.D., Ph.D., Vice President, Head of U.S. CEEDD, GSK. Protea Biosciences develops and commercializes new technology that improves the recovery and analysis of proteins from biological samples, and applies its knowledge to the development of new pharmaceuticals, life science products and services.
For more Information:
Steve Turner, CEO, stephen.turner@proteabio.com
Protea Biosciences, Inc.,
955 Hartman Run Road, Morgantown, WV 26507Phone: 304.292.2226
304.292.7101
Weblink: http://www.proteabio.com
For more information on the 2009 Boston Biotech R&D Conference, visit
www.bostonbiotechconference.com.
Posted by Matt Livengood on October 9, 2009 at 2:10 pm in the following categories: Protea Biosciences
